Dermatology Drugs Market Industry: A Latest Research Report to Share Market Insights and Dynamics

22/ago/2019 10:42:11 MonicaK Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

New York, NY 22 August 2019: The dermatology drugs market is highly fragmented but offer several commercial opportunities. There remains significant unmet need for safer and cost-effective treatment options. Psoriasis market was nearly USD 6 billion markets in 2016 due to the existing effective TNF alpha treatments. In Acne, retinoids and antibiotics are the mainstay treatments but what makes this indication lucrative is the promising candidates in the pipeline including Foamix’s FMX-101 and Dermira’s DRM-101.

 

Get sample copy of this report @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-sample

 

Polaris Market Research assumes that with the expected launch of the potential promising therapies, the market is anticipated to expand in both psoriasis and atopic dermatitis segments. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is due to the increased adoption of high priced biologics. Despite the launch and availability of multiple biologics, only 10% of the patients have access to these treatments and the market continues to remain underpenetrated.

 

 

Polaris Market Research has provided the forecasts of the Global Dermatology Drugs Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

·         Market Analysis by Dermatology Key Indications

·         Market Analysis by Treatment Class/Marketed Drugs

·         Market Analysis by Regions

Complete Summary with TOC Available @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market

 

The Marketed Therapies undertaken in forecast from 2016-2022 are:

·         etanercept; Enbrel

·         infliximab; Remicade

·         adalimumab; Humira

·         ustekinumab; Stelara

·         secukinumab; Cosentyx

·         ixekizumab; Taltz

·         golimumab; Simponi

·         brodalumab; Siliq

·         guselkamab; Tremfya

·         Topical Drugs

·         Oral Antibiotics

Market Forecast by Regions (2016-2022)

  • North America- Market Forecast (2016-2022)
  • Europe- Market Forecast (2016-2022)
  • APAC-Market Forecast (2016-2022)
  • ROW- Market Forecast (2016-2022)

Avail discount on this report @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world.

 

Contact us-

 

Mr. Rohit

Corporate Sales, USA

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com 

Web: www.polarismarketresearch.com

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl